UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

~~Form~~FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~November~~February 3029, ~~2015~~ 2016

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to_________________________ ~~Commission File Number~~to ~~333-190391~~ _________________________

Commission File Number 333-190391

SCIENCE TO CONSUMERS, INC.
(Exact name of registrant as specified in its charter)

Nevada	33-1227949
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)
Faraday Str. 31, Leipzig, Germany	04159
(Address of principal executive offices)	(Zip Code)

Faraday Str. 31, Leipzig, Germany	04159
(Address of principal executive offices)	(Zip Code)

49 (0) 1738264717
(Registrant’s telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
[X] YES [ ] NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
[X] YES [ ] NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ] (Do not check if a smaller reporting company)	Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) [ ] YES [X] NO

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.
[ ] YES [ ] NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 31,920,000 common shares issued and outstanding as of ~~January~~ 14May 17, 2016.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION		3
Item 1.	Financial Statements	3
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operation	6
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	1213
Item 4.	Controls and Procedures	13
PART II – OTHER INFORMATION		13
Item 1.	Legal Proceedings	13
Item 1A.	Risk Factors	13
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	13
Item 3.	Defaults Upon Senior Securities	13
Item 4.	Mine Safety Disclosures	14
Item 5.	Other Information	14
Item 6.	Exhibits	15
SIGNATURES		16

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

The condensed interim financial statements of our company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

3SCIENCE TO CONSUMERS, INC.

~~SCIENCE~~CONDENSED TOFINANCIAL ~~CONSUMERS,~~STATEMENTS ~~INC.~~

~~CONDENSED~~FEBRUARY ~~FINANCIAL~~29, ~~STATEMENTS~~2016

~~NOVEMBER~~SCIENCE 30TO CONSUMERS, ~~2015~~INC.

4TABLE OF CONTENTS

~~SCIENCE~~FEBRUARY ~~TO CONSUMERS~~29, ~~INC.~~2016

TABLE OF CONTENTS

Condensed Balance Sheets as of February 29, 2016 (Unaudited) and May 31, 2015	F-3

Condensed Statements of Operations for the Three and Nine Month Periods Ending February 29, 2016 and 2015 (Unaudited)	F-4

Condensed Statements of Cash Flows for the Three Month Periods Ending February 29, 2016 and 2015 (Unaudited)	F-5

Notes to the Condensed Financial Statement (Unaudited)	F-6 - F-9

~~NOVEMBER~~SCIENCE 30TO CONSUMERS, ~~2015~~INC. CONDENSED BALANCE SHEETS

Condensed Balance Sheets as of November 30, 2015 and May 31, 2015 (Unaudited)	F-1
		February 29,			May 31,
Condensed Statements of Operations for the Three and Six Month Periods Ending November 30, 2015 and 2014 (Unaudited)	F-2
		2016			2015
Condensed Statements of Cash Flows for the Six Month Periods Ending November 30, 2015 and 2014 (Unaudited)	F-3
		(Unaudited)
Notes to the Condensed Financial Statement (Unaudited)	F-4 - F-6
ASSETS
Current Assets
Cash and cash equivalents	$	–		$	1,749
Total Current Assets		–			1,749
Website development costs		9,871			–
Total Assets	$	9,871		$	1,749
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Liabilities
Current Liabilities
Accounts payable		24,304			–
Due to related party		5,698			–
Loan from director		8,891			8,891
Total Liabilities		38,893			8,891
Stockholders’ Deficit
Common stock, par value $0.001; 525,000,000 shares authorized, 31,943,833 shares (May 31, 2015 – 29,900,000 shares) issued and outstanding;		31,944			29,900
Additional paid in capital		72,206			61,100
Accumulated deficit		(133,172	)		(98,142	)
Total Stockholders’ Deficit		(29,022	)		(7,142	)
Total Liabilities and Stockholders’ Deficit	$	9,871		$	1,749

5See accompanying notes to condensed financial statements.

SCIENCE TO CONSUMERS, INC. CONDENSED ~~BALANCE SHEETS~~STATEMENTS OF OPERATIONS(Unaudited)

		November 30,			May 31,
		For the			For the			For the			For the
ASSETS		2015			2015
		three month			three month			nine month			nine month
Current Assets
		period ended			period ended			period ended			period ended
Cash and cash equivalents	$	614		$	1,749
		February 29,			February 28,			February 29,			February 28,
Total Current Assets		614			1,749
		2016			2015			2016			2015
Website development costs, net		10,162			–
REVENUES	$	–		$	–		$	–		$	–
Total Assets	$	10,776		$	1,749
OPERATING EXPENSES
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Advertising and Promotion		–			–			–			15
Liabilities
Amortization Expense		291			–			581			–
Current Liabilities
Bank Service Charges		–			48			–			169
Accounts payable	$	18,765		$	–
Professional Fees		18,501			11,866			34,449			40,856
Accrued liabilities		500			–
TOTAL OPERATING EXPENSES		18,792			11,914			35,030			41,040
Loan from director		8,891			8,891
NET LOSS FROM OPERATIONS		(18,792	)		(11,914	)		(35,030	)		(41,040	)
Total Liabilities		28,156			8,891
PROVISION FOR INCOME TAXES		–			–			–			–
Stockholders’ Deficit
NET LOSS	$	(18,792	)	$	(11,914	)	$	(35,030	)	$	(41,040	)
Common stock, par value $0.001; 525,000,000 shares authorized, 29,920,000 shares (May 31, 2015 – 29,900,000 shares) issued and outstanding;		29,920			29,900
NET LOSS PER SHARE: BASIC AND DILUTED	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
Additional paid in capital		67,080			61,100
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED		31,568,000			29,900,000			30,465,000			29,900,000
Accumulated deficit		(114,380	)		(98,142	)
Total Stockholders’ Deficit		(17,380	)		(7,142	)
Total Liabilities and Stockholders’ Deficit	$	10,776		$	1,749

See accompanying notes to condensed financial statements.

~~F-1~~SCIENCE TO CONSUMERS, INC.CONDENSED STATEMENTS OF CASH FLOWS(Unaudited)

SCIENCE TO CONSUMERS, INC.CONDENSED STATEMENTS OF OPERATIONS(Unaudited)

		For the			For the
		nine months			nine months
		ended			ended
		February 29,			February 28,
		2016			2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$	(35,030	)	$	(41,040	)

Adjustments to reconcile net loss:
Amortization		581			–

Changes in assets and liabilities:
Accounts payable and accrued liabilities		13,852			–
CASH FLOWS USED IN OPERATING ACTIVITIES		(20,597	)		(41,040	)

CASH FLOWS FROM FINANCING ACTIVITIES

Advances from related party		5,698			–
Loans from director		–			674
Proceeds from sale of common stock		13,150			45,000
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		18,848			45,674


NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(1,749	)		4,634
Cash and cash equivalents, beginning of period		1,749			5,171
Cash and cash equivalents, end of period	$	–		$	9,805

SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid	$	–		$	–
Income taxes paid	$	–		$	–

		For the			For the			For the			For the
		three month			three month			six month			six month
		period ended			period ended			period ended			period ended
		November 30,			November 30,			November 30,			November 30,
		2015			2014			2015			2014
REVENUES	$	–		$	–		$	–		$	–
OPERATING EXPENSES
Advertising and Promotion		–			–			–			15
Amortization Expense		290			–			290			–
Bank Service Charges		–			60			–			120
Professional Fees		11,831			25,327			15,948			28,990
TOTAL OPERATING EXPENSES		12,121			25,387			16,238			29,125
NET LOSS FROM OPERATIONS		(12,121	)		(25,387	)		(16,238	)		(29,125	)
PROVISION FOR INCOME TAXES		–			–			–			–
NET LOSS	$	(12,121	)	$	(25,387	)	$	(16,238	)	$	(29,125	)
NET LOSS PER SHARE: BASIC AND DILUTED	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED		29,917,802			29,872,527			29,908,852			29,900,000

See accompanying notes to condensed financial statements.

~~See~~NOTE ~~accompanying~~1 ~~notes~~– toORGANIZATION ~~condensed~~AND ~~financial~~NATURE ~~statements.~~ OF BUSINESS

FScience to Consumers, Inc. is a development stage company registered in the State of Nevada on April 15, 2013 formed to distribute Argan Oil products. Science to Consumers, Inc. will position itself to take full advantage of the distributing Argan oil products from manufacturers to customers. In addition, the Company signed a five-2year exclusive licensing agreement with Biomatrix, Inc. for the People’s Republic of China and Europe. Science to Consumers, Inc., is also focused on anti-aging and good-for-your-body products. The agreement will allow Science to Consumers Inc., to market and sell at least six of its special formulated anti-aging products including the DermaLastyl line.

~~SCIENCE~~NOTE TO2 ~~CONSUMERS,~~– ~~INC.~~CONDENSED FINANCIAL STATEMENTS ~~OF CASH FLOWS(Unaudited)~~

		For the			For the
		six months			six months
		ended			ended
		November 30,			November 30,
		2015			2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$	(16,238	)	$	(29,125	)
Adjustments to reconcile net loss:
Amortization		290			–
Changes in assets and liabilities:
Accounts payable and accrued liabilities		19,265			–
CASH FLOWS USED IN OPERATING ACTIVITIES		3,317			(29,125	)
CASH FLOWS FROM INVESTING ACTIVITIES
Website		(10,452	)		-
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		(10,452	)		-
CASH FLOWS FROM FINANCING ACTIVITIES
Loans from director		–			1,998
Proceeds from sale of common stock		6,000			45,000
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		6,000			46,998
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(1,135	)		17,873
Cash and cash equivalents, beginning of period		1,749			5,171
Cash and cash equivalents, end of period	$	614		$	23,044
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid	$	-		$	-
Income taxes paid	$	-		$	-

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial positions, results of operations, and cash flows on February 29, 2016, and for all periods presented herein, have been made.

~~See~~Certain ~~accompanying~~information ~~notes~~and tofootnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s May 31, 2015 audited financial statements. The results of operations for the nine months ended February 29, 2016 are not necessarily indicative of the operating results for the full year.

F-NOTE 3 – SUMMARY OF SIGNIFCANT ACCOUNTING POLICIES

~~SCIENCE~~Basis TOof ~~CONSUMERS,~~Presentation ~~INC.~~The ~~NOTES~~financial TOstatements ~~CONDENSED~~of ~~FINANCIAL~~the ~~STATEMENTS~~Company ~~NOVEMBER~~have ~~30,~~been ~~2015~~prepared ~~(Unaudited)~~in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

~~NOTE~~Accounting 1Basis –The ~~ORGANIZATION~~Company ~~AND~~uses ~~NATURE~~the OFaccrual ~~BUSINESS~~basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting). The Company has adopted a May 31 fiscal year end.

~~Science~~Cash toand ~~Consumers,~~Cash ~~Inc.~~Equivalents isThe aCompany ~~start-up~~considers ~~company~~all highly ~~registered~~liquid ~~in the~~investments ~~State~~with ofthe ~~Nevada~~original onmaturities ~~April~~of ~~15,~~three ~~2013~~months ~~formed~~or less to ~~distribute~~be ~~Argan~~cash ~~Oil products~~equivalents. ~~Science~~ toThe ~~Consumers,~~Company ~~Inc.~~had ~~will~~$nil ~~position~~of ~~itself~~cash toas ~~take~~of ~~full~~February ~~advantage~~29, of2016 ~~the~~and ~~distributing~~$1,749 ~~Argan~~of ~~oil~~cash ~~products~~as ~~from~~of ~~manufacturers~~May to31, ~~customers~~2015.

~~NOTE~~Fair 2Value -of ~~CONDENSED~~Financial ~~FINANCIAL~~Instruments ~~STATEMENTS~~The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities, amounts due to a related party and a loan from a director. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

~~The~~Website ~~accompanying~~Development ~~financial~~CostsWebsite ~~statements~~development ~~have~~costs consist ~~been~~of ~~prepared~~costs byincurred ~~the Company~~to ~~without~~develop ~~audit.~~internet Inwebsites ~~the~~to ~~opinion of management~~promote, ~~all adjustments (which~~advertise, ~~include~~and ~~only~~earn ~~normal~~revenue ~~recurring~~with ~~adjustments)~~respect ~~necessary~~ to ~~present~~the ~~fairly~~Company’s ~~the financial~~business ~~positions,~~operations. ~~results~~Costs ofare amortized ~~operations,~~on ~~and~~a ~~cash~~straight ~~flows~~line onbasis ~~November~~over ~~30,~~3 ~~2015, and~~years ~~for~~from ~~all~~when ~~periods~~the ~~presented~~internet ~~herein,~~web ~~have~~site has been ~~made~~completed.

~~Certain~~Income ~~information~~Taxes ~~and~~Income ~~footnote~~taxes ~~disclosures~~are ~~normally~~computed ~~included in~~using the asset ~~financial~~and ~~statements~~liability ~~prepared~~method. inUnder ~~accordance~~the ~~with~~asset ~~accounting~~and ~~principles generally~~liability ~~accepted~~method, indeferred income ~~the~~tax ~~United~~assets ~~States~~and ofliabilities ~~America~~are ~~have~~determined ~~been~~based ~~condensed~~on orthe differences ~~omitted.~~between Itthe ~~is suggested that these condensed~~ financial ~~statements~~reporting beand ~~read~~tax ~~in conjunction~~bases ~~with~~of ~~the~~assets ~~financial~~and ~~statements~~liabilities and ~~notes~~are measured ~~thereto~~using ~~included in~~ the ~~Company’s~~ ~~May~~currently ~~31,~~enacted ~~2015~~tax ~~audited~~rates ~~financial~~and ~~statements~~laws. ~~The~~A ~~results~~valuation ~~of operations~~allowance is provided for the ~~six~~amount ~~months~~of ~~ended~~deferred ~~November~~tax 30assets that, ~~2015~~based ~~are~~on ~~not necessarily indicative of the~~available ~~operating~~evidence, ~~results~~are ~~for~~not ~~the~~expected ~~full~~to ~~year~~be realized.

~~NOTE~~Use 3of –Estimates ~~SUMMARY~~ The OFpreparation ~~SIGNIFCANT~~of ~~ACCOUNTING~~financial statements ~~POLICIES~~in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

~~Basis~~Revenue ofRecognition ~~Presentation~~ The Company recognizes revenue when products are fully delivered or services have been provided and collection is reasonably assured.

~~The~~Stock-Based ~~financial~~Compensation ~~statements~~Stock-based ofcompensation ~~the~~is accounted ~~Company~~for ~~have~~at ~~been~~fair ~~prepared~~value in accordance with ~~generally~~ASC ~~accepted~~Topic ~~accounting~~718. ~~principles~~To indate, the Company ~~United~~has ~~States~~not ~~of America~~adopted a stock option plan and ~~are~~has ~~presented~~not ingranted USany ~~dollars~~stock options.

~~Accounting~~Basic ~~Basis~~Income (Loss) Per Share Basic income (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of February 29, 2016 and May 31, 2015.

Comprehensive Income The Company ~~uses~~has ~~the~~which established ~~accrual~~standards ~~basis~~for reporting and display of ~~accounting~~comprehensive ~~and~~income, ~~accounting~~its ~~principles~~components ~~generally~~and ~~accepted~~accumulated inbalances. When applicable, the ~~United~~Company ~~States~~would disclose this information on its Statement of ~~America~~Stockholders’ ~~(“GAAP”~~Equity. Comprehensive income ~~accounting)~~comprises equity except those resulting from investments by owners and distributions to owners. The Company has ~~adopted~~not ahad ~~May~~any 31significant ~~fiscal~~transactions that ~~year~~are ~~end~~required to be reported in other comprehensive income.

~~Cash~~NOTE ~~and~~4 ~~Cash~~– ~~Equivalents~~GOING CONCERN

The ~~Company~~accompanying ~~considers~~financial ~~all~~statements ~~highly~~have ~~liquid~~been ~~investments~~prepared in conformity with ~~the original~~generally ~~maturities~~accepted ofaccounting ~~three~~principle, ~~months~~which orcontemplate continuation ~~less~~of tothe beCompany ~~cash~~as ~~equivalents~~a going concern. ~~The~~However, the Company had ~~$614~~no revenues ~~of cash~~ as of ~~November~~February 3029, ~~2015~~2016. ~~and~~The $1Company currently has working capital deficit,~~749~~ ofand ~~cash~~has asnot completed its efforts to establish a stabilized source of revenues ~~May~~sufficient ~~31,~~to ~~2015.~~cover operating costs over an extended period of time.

~~Fair~~Management ~~Value~~anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of ~~Financial~~management’s ~~Instruments~~efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

~~The~~NOTE ~~Company’s~~5 ~~financial~~– ~~instruments~~LICENSE ~~consist~~AGREEMENT ofDEPOSIT cash and cash equivalents, accounts payable, accrued liabilities, and loan from director. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

~~Website~~On ~~Development~~December ~~Costs~~29, 2015, the Company entered into an exclusive license agreement with Biomatrix Inc. (“Biomatrix”), a Delaware corporation, pursuant to which the Company obtained the exclusive rights to sell certain proprietary skincare products of Biomatrix by direct to consumer marketing and sales in the territories of China and Europe. In consideration for the marketing, sales and distribution services to be provided by the Company, Biomatrix has agreed to supply product inventory at a rate not less favorable than that provided to any third party. Additionally, Biomatrix has agreed to transfer to the Company 100% equity ownership of Biomatrix Inc. (“Biomatrix Arizona”), an Arizona corporation, which holds all right and title to the product distribution rights acquired. In consideration of transfer of title and rights acquired, the Company issued 2,000,000 restricted shares of common stock to Biomatirx. Upon closing of the transaction, Biomatrix Arizona will become a wholly owned subsidiary of the Company. As of February 29, 2016, the transaction had not closed and the Company has not received ownership of the Biomatrix Arizona equity.

~~Website~~The ~~development~~initial ~~costs~~term ~~consist~~ of ~~costs~~the exclusive license agreement is 5 years, ~~incurred~~subject to ~~develop~~the ~~internet~~Company ~~websites~~achieving tominimum ~~promote~~sales of $250,000 ~~advertise~~and $500,000 during the first and ~~earn~~second ~~revenue~~years of the agreement, respectively. Thereafter, the term ~~with~~will ~~respect~~automatically torenew for successive 5 year periods provided that the Company’s ~~business~~achieve ~~operations.~~a ~~Costs~~minimum ~~are~~$500,000 ~~amortized~~in onsales ~~a straight~~of ~~line~~the ~~basis~~licensed ~~over~~products 3during each ~~years~~calendar ~~from~~year ~~when~~of the ~~internet~~term, ~~web~~excluding ~~site~~the ~~has~~first ~~been completed~~year.

~~Income~~On ~~Taxes~~December 16, 2015, the Company issued Biomatrix 2,000,000 shares of the Company’s common stock pursuant to the license agreement. As of February 29, 2016, the shares of Biomatrix Arizona were not received by the Company and the transaction had not closed. Due to the value of Biomatrix Arizona and the Company’s uncertain future revenues generated by the license, the fair value of the 2,000,000 shares issued has been recorded as $nil.

~~Income~~NOTE ~~taxes~~6 ~~are~~– ~~computed~~DUE ~~using~~TO ~~the~~RELATED ~~asset~~PARTY and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

~~Use~~As of ~~Estimates~~February 29, 2016, the Company was indebted to the Chief Executive Officer of the Company for $5,698 (May 31, 2015 - $nil), for expenses paid on behalf of the Company. The amount is unsecured, non-interest bearing and due on demand.

~~The~~NOTE ~~preparation~~7 of– ~~financial~~LOAN ~~statements~~FROM inDIRECTOR conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

FAs of February 29, 2016, the Company owed a director of the Company $8,891 (May 31, 2015 -4 $8,891) related to a loan to the Company for business operations. The loan is unsecured, non-interest bearing and due on demand.

~~SCIENCE~~NOTE TO8 ~~CONSUMERS,~~– ~~INC.~~COMMON ~~NOTES~~STOCK ~~TO CONDENSED FINANCIAL STATEMENTS NOVEMBER 30, 2015 (Unaudited)~~

~~Revenue~~The ~~Recognition~~Company has 525,000,000, $0.001 par value shares of common stock authorized.

~~The~~On ~~Company~~September ~~recognizes~~11, ~~revenue~~2015, ~~when~~the ~~products~~Company ~~are~~issued ~~fully delivered~~20,000 orshares ~~services~~of stock ~~have~~at ~~been~~$0.30 ~~provided~~per ~~and~~share ~~collection~~for iscash ~~reasonably~~proceeds ~~assured~~of $6,000.

~~Stock-Based~~On ~~Compensation~~December 16, 2015, the Company issued 2,000,000 restricted shares to Biomatrix, Inc. with a fair value of $nil pursuant to the license agreement referred to Note 5.

~~Stock-based~~On ~~compensation~~December is16, ~~accounted for at fair value in accordance with ASC Topic 718. To date~~2015, the Company ~~has~~issued ~~not~~15,500 ~~adopted~~shares aof stock ~~option~~at ~~plan~~$0.30 ~~and~~per ~~has~~share ~~not~~for ~~granted~~cash ~~any~~proceeds ~~stock~~of ~~options~~$4,650.

~~Basic~~On ~~Income~~January ~~(Loss)~~20, ~~Per~~2016, ~~Share~~the Company issued 8,333 shares of stock at $0.30 per share for cash proceeds of $2,500.

~~Basic~~There ~~income~~were ~~(loss)~~31,943,833 ~~per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common~~ shares ~~during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number~~ of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock ~~equivalents~~issued and outstanding as of February ~~November 30~~29, ~~2015 and May 31, 2015~~2016.

~~Comprehensive~~NOTE ~~Income~~9 – WARRANTS

The ~~Company~~following ~~has~~table ~~which~~summarizes ~~established standards for reporting and display of comprehensive income, its components and accumulated balances. When applicable,~~ the ~~Company~~continuity ~~would disclose this information on its Statement~~ of ~~Stockholders’~~share ~~Equity. Comprehensive income comprises equity except~~purchase ~~those~~warrants: ~~resulting from investments by owners and distributions to owners. The Company has not had any significant transactions that are required to be reported in other comprehensive income.~~

NOTE 4 – GOING CONCERN

		Weighted
		Average
	Number of	Exercise Price
	Warrants	$

Balance, May 31, 2014	–	–
Issued	150,000	0.50
Balance, May 31, 2015 and February 29, 2016	150,000	0.50

~~The~~As ~~accompanying~~at ~~financial~~February ~~statements have been prepared in conformity with generally accepted accounting principle~~29, ~~which contemplate continuation of the Company as a going concern. However~~2016, the ~~Company~~following ~~had~~share ~~no revenues~~purchase ~~as of November 30, 2015. The Company currently has limited working~~warrants ~~capital,~~were ~~and~~outstanding: ~~has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time.~~

Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

	Exercise
	Price		Weighted Average
Number of Warrants	$	Expiry Date	Remaining Life (years)
50,000	0.50	September 17, 2017	1.55
100,000	0.50	September 18, 2017	1.55

150,000			1.55

NOTE 510 – ~~LOAN~~COMMITMENTS ~~FROM~~AND ~~DIRECTOR~~CONTINGENCIES

AsThe ofCompany ~~November~~neither ~~30,~~owns ~~2015,~~nor ~~the~~leases ~~Company~~any ~~owed~~real aor ~~director~~personal property. ofAn ~~the Company~~officer ~~$8,891~~has ~~(May~~provided ~~31,~~office ~~2015~~services -without ~~$8,891)~~charge. ~~related~~There is no obligation for the officer to acontinue ~~loan~~this arrangement. Such costs are immaterial to the ~~Company~~financial ~~for business~~statements ~~operations.~~and accordingly are not reflected herein. The ~~loans~~officers and directors are ~~unsecured,~~involved ~~non-interest~~in ~~bearing~~other ~~and~~business ~~due~~activities onand most ~~demand~~likely will become involved in other business activities in the future.

NOTE 611 – ~~COMMON~~SUBSEQUENT ~~STOCK~~EVENTS

~~The~~In accordance with SFAS 165 (ASC 855-10) the Company has analyzed ~~525,000,000,~~its ~~$0.001~~operations ~~par~~subsequent ~~value~~to ~~shares~~February of29, ~~common~~2016 to the date these ~~stock~~financial ~~authorized~~statements were issued.

OnItem ~~September~~2. ~~11,~~Management's ~~2015,~~Discussion ~~the~~and ~~Company~~Analysis ~~issued 20,000 shares~~ of ~~stock~~ atFinancial ~~$0.30~~Condition ~~per~~and ~~share~~Results ~~for cash proceeds~~ of ~~$6,000.~~ Operation

~~There~~FORWARD-LOOKING ~~were 29,920,000 shares of common stock issued and outstanding as of November 30, 2015.~~ STATEMENTS

FThis quarterly report contains forward-5looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

~~SCIENCE~~Our TOunaudited ~~CONSUMERS~~condensed financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, ~~INC~~estimates and beliefs. ~~NOTES~~Our actual TOresults ~~CONDENSED~~could differ materially from those discussed in the ~~FINANCIAL~~forward-looking ~~STATEMENTS~~statements. ~~NOVEMBER~~Factors 30that could cause or contribute to such differences include, ~~2015~~but ~~(Unaudited)~~are not limited to, those discussed below and elsewhere in this quarterly report.

~~NOTE~~Unless 7otherwise –specified ~~WARRANTS~~in this quarterly report, all dollar amounts are expressed in United States dollars and all references to “common stock” refer to shares of our common stock.

~~The~~As ~~following~~used ~~table~~in ~~summarizes~~this quarterly report, the ~~continuity~~terms of“we”, ~~share~~“us”, ~~purchase~~“our” ~~warrants:~~and “our company” mean Science to Consumers, Inc., unless the context clearly requires or states otherwise.

		Weighted
		Average
	Number of	Exercise Price
	Warrants	$
Balance, May 31, 2014	–	–
Issued	150,000	0.50
Balance, May 31, 2015 and November 30, 2015	150,000	0.50

Corporate Overview

AsWe atwere ~~November~~incorporated 30in the State of Nevada on April 15, ~~2015~~2013. Our company is planning to be a distributor of Argan oil and Argan oil products to stores, spas, massage therapy offices and individuals in Germany. We intend to bring the ~~following~~100% ~~share~~pure ~~purchase~~and ~~warrants~~organic Argan oil and skin products made with Argan ~~were~~oil ~~outstanding:~~directly from the manufacturers in Morocco to Germany and in the future to the rest of Europe. We expect to generate revenues from sales of our products to individual customers and commercial customers such as spas, stores and massage therapy offices. Both individual and commercial customers will be able to order our products by telephone, our website has been updated and changed to reflect our name change to www.sciencetoconsumers.com.

	Exercise
	Price		Weighted Average
Number of Warrants	$	Expiry Date	Remaining Life (years)
50,000	0.50	September 17, 2017	1.80
100,000	0.50	September 18, 2017	1.80
150,000			1.80

At this stage, we have no revenues. The past operations had the Company engaged in preparing our business plan and the development of our website and e-commerce shopping cart. Our potential client list consists of 4 companies ranging from beauty stores, spas massage therapy offices, and cosmetic distributors.

~~NOTE~~The 8majority –of ~~COMMITMENTS~~our ~~AND~~business ~~CONTINGENCIES~~will be initially marketed in China, Hong Kong, and Germany but as our operations expand, we plan to expand to other European markets. We are also looking at opportunities to expand our operations and expand product lines in the USA, European, and Asian markets.

~~The~~ Our ~~Company~~company ~~neither~~will ~~owns~~focus ~~nor~~on ~~leases~~providing helpful ~~any~~customer ~~real~~service. orWe ~~personal property.~~are Ancurrently ~~officer~~selling ~~has~~six ~~provided~~products ~~office~~that ~~services~~are available ~~without~~to ~~charge.~~be ~~There~~purchased isthrough ~~no obligation~~our ~~for~~website, ~~the~~and ~~officer~~wholesale toorders ~~continue~~are ~~this~~also being ~~arrangement.~~accepted ~~Such~~from ~~costs~~June ~~are immaterial~~1, to2016. ~~the~~The Company ~~financial~~plans ~~statements~~on ~~and~~engaging ~~accordingly~~in ~~are~~an ~~not~~e-commerce ~~reflected~~strategy ~~herein. The~~to ~~officers~~be ~~and~~able ~~directors~~to ~~are~~drive ~~involved~~its online insales. ~~other~~In ~~business~~addition, ~~activities~~the ~~and~~company is ~~most likely~~targeting ~~will~~cosmetic ~~become~~distribution ~~involved~~companies in ~~other~~China ~~business~~and ~~activities~~Hong inKong ~~the~~as ~~future.~~part of its sales strategy.

~~NOTE~~The 9Company –is ~~SUBSEQUENT~~also ~~EVENTS~~working with the Licensee to re-design and re-package the product line to better reflect the Chinese market place.

On One ~~December~~June 291, ~~2015~~2013, ~~the~~we ~~Company~~ entered into ana ~~exclusive license~~web site design agreement with ~~Biomatrix~~Smart ~~Inc~~Creations., anAs ~~Arizona corporation~~compensation, ~~pursuant~~our tocompany ~~which the~~will ~~Company~~pay ~~obtained~~Smart ~~the~~Creations ~~exclusive~~$300 ~~rights~~upon tocompletion ~~sell~~of ~~certain~~the ~~proprietary~~creation ~~skincare products~~ of ~~Biomatrix~~our bycompany’s ~~direct~~website towhich ~~consumer~~was ~~marketing~~estimated ~~and~~to ~~sales~~be incompleted ~~the~~on ~~territories~~October of30, ~~China and Europe~~2013. InWe ~~consideration~~have ~~for~~since ~~the~~re-designing ~~marketing,~~our ~~sales~~website ~~and distribution~~in ~~services~~order to bebetter ~~provided~~market byour ~~the~~brand ~~Company,~~and ~~Biomatrix~~image ~~has agreed~~ to ~~supply~~ ~~product~~consumers ~~inventory~~and atto abetter ~~rate~~reflect ~~not~~our ~~less~~existing ~~favorable than that provided to any third party~~business. ~~Additional,~~We ~~Biomatrix~~will ~~has~~always ~~agreed~~look toat ~~transfer~~updating toour ~~the~~website ~~Company~~as ~~100% equity~~we ~~ownership~~grow ~~of Biomatrix Inc., which holds all right~~ and ~~title~~as toour ~~the product~~business ~~distribution rights acquired~~evolves. ~~In consideration of transfer of title and~~The ~~rights~~re-design ~~acquired,~~should ~~the~~be ~~Company~~completed ~~issued~~prior ~~2,000,000~~to ~~restricted~~October ~~shares of common stock. Upon closing of the transaction~~31, ~~Biomatrix will become a wholly owned subsidiary of the Company~~2015.

~~The~~ On ~~initial~~July ~~term~~31, of2014, ~~the~~our ~~exclusive~~company’s ~~license~~board ~~agreement~~of isdirectors 5approved ~~years, subject~~a resolution to ~~the~~effect ~~Company~~a ~~achieving~~7 ~~minimum~~new ~~sales~~for 1 old forward split of ~~$250,000~~our authorized and ~~$500,000~~our ~~during the~~issued ~~first~~ and ~~second~~outstanding ~~years~~shares of ~~the~~common ~~agreement, respectively~~stock. ~~Thereafter,~~A Certificate of Change for the ~~term~~stock split was filed ~~will~~and ~~automatically~~became ~~renew~~effective ~~for~~with ~~successive~~the 5Nevada ~~year~~Secretary ~~periods~~of ~~provided~~State ~~that~~on ~~the~~August ~~Company achieve~~19, a2014. ~~minimum~~Consequently, ~~$500~~our authorized share capital increased from 75,000,000 into ~~sales~~525,000,000 shares of ~~the~~common ~~licensed~~stock ~~products~~and ~~during~~our ~~each~~issued and outstanding common stock, at that time, ~~calendar~~increased ~~year~~from of4,250,000 ~~the~~to ~~term~~29,900,000 ~~excluding~~shares, ~~the~~all ~~first~~with ~~year~~a par value of $0.001.

In The ~~accordance~~forward ~~with~~stock ~~SFAS~~split ~~165~~was ~~(ASC~~approved ~~855-10)~~by the ~~Company~~Financial ~~has analyzed~~Industry ~~its~~Regulatory ~~operations~~Authority ~~subsequent~~(FINRA) towith ~~November~~an ~~30,~~effective ~~2015 to the~~ date ~~these financial~~of ~~statements~~August ~~were~~19, ~~issued~~2014.

F On November 25, 2014, our board of directors approved an agreement and plan of merger to merge with our wholly-6owned subsidiary Science to Consumers, Inc., a Nevada corporation, to effect a name change from Argan Beauty Corp. to Science to Consumers, Inc. Science to Consumers, Inc. was formed solely for the change of name.

~~Item~~ Articles 2.of ~~Management's~~Merger ~~Discussion~~to effect the merger and ~~Analysis~~change of ~~Financial~~name ~~Condition~~were filed and ~~Results~~became effective with the Nevada Secretary of ~~Operation~~State on December 23, 2014. The name change was reviewed by the FINRA and was approved for filing with an effective date of December 24, 2014. The name change became effective with the Over-the-Counter Bulletin Board at the opening of trading on December 24, 2014 under the symbol "BEUT". Our CUSIP number is 808645105.

~~FORWARD-LOOKING~~ Effective ~~STATEMENTS~~August 18, 2015, Burt Ensley resigned as chief executive officer of our company. Mr. Ensley will remain as a company advisor. In connection with the resignation of Mr. Ensley, Edwon Lam was appointed as chief executive officer.

~~This quarterly report contains forward-looking statements.~~ ~~These statements relate to future events or our future financial performance~~Mr. ~~In some~~Ensley's ~~cases,~~resignation ~~you~~was ~~can~~not identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the ~~negative~~result of ~~these~~any ~~terms~~disagreement orwith ~~other comparable~~our ~~terminology.~~company ~~These~~regarding ~~statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause~~ our ~~or our industry's actual results~~operations, ~~levels of activity~~policies, ~~performance~~practices or ~~achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements~~otherwise. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our ~~unaudited~~principal ~~condensed~~executive ~~financial~~office ~~statements~~is ~~are~~located ~~stated~~at ~~in United~~Faraday ~~States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles~~Str. ~~The~~31, ~~following~~Leipzig, discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plansGermany, ~~estimates and beliefs~~04159. Our ~~actual~~ ~~results~~telephone ~~could~~number ~~differ~~is ~~materially~~49 ~~from~~(0) ~~those~~173 ~~discussed~~8264 ~~in the forward-looking statements~~717. ~~Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.~~

~~Unless otherwise specified in this quarterly report, all dollar~~ ~~amounts~~Our ~~are~~Current ~~expressed~~Business ~~in United States dollars and all references to “common stock” refer to shares of our common stock.~~

As On ~~used~~October in1, ~~this~~2013, ~~quarterly~~Science ~~report~~to Consumers Inc., ~~the~~a ~~terms~~private ~~“we”,~~Nevada corporation (the “usAssignor”), ~~“our” and~~entered ~~“our~~into ~~company”~~a ~~mean~~License ~~Science~~Agreement towith ~~Consumers,~~Protein Genomics Inc., ~~unless~~a Delaware corporation, pursuant to which the ~~context~~Assignor ~~clearly~~acquired the rights from ~~requires~~Protein orGenomics ~~states~~Inc. ~~otherwise~~to sell certain products.

~~Corporate~~ On ~~Overview~~January 19, 2015, our company, as assignee, entered into an Assignment Agreement with the Assignor, pursuant to which we have acquired the right, title and interest to the License Agreement and all obligations, benefits and advantages thereunder in relation to the territory under the License Agreement for consumer skin care products supplied by Protein Genomics. Under the terms of the Assignment Agreement, Burt Ensley, the current sole director and officer of the Assignor and a former chief executive officer of our company, shall be issued 2,000,000 shares of common stock of our company as consideration for the transfer of the License Agreement.

We Under ~~were incorporated in~~ the ~~State~~License ofAgreement ~~Nevada~~our ~~on April 15, 2013. Our~~ company iswill ~~planning~~provide todirect ~~be a distributor of Argan oil and Argan oil products~~ to ~~stores,~~consumer ~~spas~~sales, ~~massage~~marketing ~~therapy offices~~ and ~~individuals~~distribution inof ~~Germany.~~finished Weconsumer ~~intend to bring the 100% pure and organic Argan oil and~~ skin care products ~~made~~provided ~~with~~by ~~Argan oil~~Protein ~~directly~~Genomics ~~from~~via ~~the~~direct ~~manufacturers~~response inadvertisements ~~Morocco to Germany~~ and inother ~~the~~worldwide ~~future~~marketing ~~to the rest of Europe. We expect to generate revenues from sales of our products to individual customers~~ and ~~commercial customers such as spas, stores and massage~~ ~~therapy~~distribution ~~offices~~channels. ~~Both~~Our ~~individual~~company ~~and commercial customers~~ will becreate ~~able~~direct toresponse ~~order our~~advertisements ~~products~~for ~~by telephone, our website has been updated and changed to reflect our name change to www.sciencetoconsumers.com. We will import 100% pure Argan oil and all~~ the ~~skin care~~ products ~~made with Argan oil straight from the manufacturer~~ in ~~Morocco~~consultation ~~and~~with ~~deliver~~Protein ~~them~~Genomics, towhich ~~our~~shall ~~clients~~initially inconsist ~~Germany without the help~~ of ~~commission~~direct ~~base~~response ~~agents.~~print Weadvertisements ~~are~~and ~~also~~television ~~looking~~commercials atand ~~securing~~ other ~~products~~forms of todirect ~~distribute~~response ~~in the North American market~~advertisements.

At Our ~~this~~company ~~stage,~~shall wemanage ~~have~~all nocreative ~~revenues.~~testing, ~~The~~media, ~~only~~buying, ~~operations~~telemarketing wefulfillment ~~have engaged~~and incredit ~~are~~card ~~preparing~~processing ~~our~~relating ~~business~~to ~~plan~~the ~~and~~sale of the ~~development~~consumer ofskin ~~our~~care ~~website. Our~~products ~~potential~~through ~~client~~direct ~~list~~response ~~consists~~advertisements ofand 4will ~~companies~~work ~~ranging~~with ~~from~~Protein ~~beauty~~Genomics ~~stores,~~on ~~spas~~appropriate publicity and ~~massage~~home ~~therapy~~shopping ~~offices~~opportunities for the products. We may also work together with respect to the packaging of the products.

~~The~~ Our ~~majority~~company ofmay ~~our~~also ~~business~~present ~~will~~buying beopportunities ~~initially~~online ~~marketed~~of ~~in Germany~~the ~~but~~products as ~~our~~part ~~operations~~of ~~expand, we plan to expand to other European markets. We are also looking at opportunities to expand~~ our ~~operations~~overall ~~and product~~web ~~lines~~strategy inincluding ~~the~~order ~~USA~~acceptance, ~~European,~~billing and ~~Asian markets~~collection.

6 Protein Genomics will provide our company with finished inventory, claims substantiation with respect to each product including any relevant clinical data and support for any such claims, assistance in securing testimonials and cooperation from experts and arranging for appearances by our former chief executive officer, Burt Ensley, to promote the products in our direct response advertising channels. Protein Genomics will also provide us with fully cleared content required by our company to create the direct response advertisements, ensure that any patents and intellectual property are in good standing and defend against any potential competition or infringement.

~~Our company will focus on providing helpful customer service.~~ WeThe ~~will~~terms ~~have vast selection~~ of ~~products~~the asAssignment ~~well~~Agreement assigned ~~same-day~~on ~~delivery~~January ~~services within~~19, ~~100~~2015 ~~miles~~have ~~radius.~~not Webeen ~~also~~met ~~offer~~and a nonew ~~minimum~~agreement ~~order~~with ~~size~~similar terms and nopricing ~~shipping charges,~~were asnegotiated ~~well~~and asentered ~~returns~~into ofon ~~unused~~December 29, ~~saleable products for an instant credit~~2015.

~~One~~ Effective ~~June~~December 129, ~~2013~~2015, we entered into aan ~~web~~exclusive ~~site~~license ~~design~~ agreement with ~~Smart~~Biomatrix ~~Creations~~Inc., Asa ~~compensation~~Delaware corporation, ~~our~~pursuant ~~company~~to ~~will~~which ~~pay~~we ~~Smart~~obtained ~~Creations~~the ~~$300 upon~~exclusive ~~completion~~rights ofto ~~the~~sell ~~creation~~certain ofproprietary ~~our~~skincare ~~company’s~~products ~~website~~of ~~which~~Biomatrix ~~was~~by ~~estimated~~direct to beconsumer ~~completed~~marketing onand ~~October~~sales ~~30,~~in ~~2013~~the territories of China and Europe. WeIn ~~have~~consideration ~~since~~for ~~re-designing~~the ~~our~~marketing, ~~website~~sales ~~in order~~and distribution services to ~~better~~be ~~market~~provided by our ~~brand~~company, ~~and~~Biomatrix ~~image~~has agreed to ~~consumers~~supply ~~and~~product toinventory ~~better~~at ~~reflect~~a rate not less favorable ~~our~~than ~~existing~~that ~~business~~provided to any third party. WeAdditionally, ~~will~~Biomatrix ~~always~~has ~~look~~agreed atto ~~updating~~transfer to our ~~website~~company as100% weequity ~~grow~~ ownership of Biomatrix Inc., an Arizona corporation which holds all right and astitle ~~our~~to ~~business~~the ~~evolves~~product distribution rights acquired. ~~The~~In consideration ~~re-design~~of ~~should~~transfer beof ~~completed~~title ~~prior~~and rights acquired, we agreed to ~~October 31~~issue to Biomatrix (Delaware) 2,000,000 ~~2015~~restricted common shares in the capital stock of our company.

On The ~~July~~initial ~~31,~~term ~~2014, our company’s board~~ of ~~directors~~the ~~approved~~exclusive ~~a resolution~~license toagreement ~~effect~~is ~~a 7 new~~ for 15 ~~old~~years, ~~forward~~subject ~~split~~to of our ~~authorized~~company ~~and~~achieving ~~our issued~~minimum ~~and~~sales ~~outstanding shares~~ of ~~common~~$250,000 ~~stock.~~and A$500,000 ~~Certificate~~during ~~of Change for~~ the ~~stock~~ ~~split~~first ~~was filed~~ and ~~became~~second ~~effective~~years ~~with~~of the ~~Nevada Secretary of State on August 19~~agreement, ~~2014~~respectively. ~~Consequently~~Thereafter, ~~our~~the ~~authorized~~term ~~share~~will automatically ~~capital~~renew ~~increased~~for ~~from 75,000,000~~successive to5 ~~525,000,000~~year ~~shares~~periods ofprovided ~~common~~that ~~stock~~we ~~and~~achieve ~~our~~a ~~issued~~minimum ~~and~~$500,000 ~~outstanding common~~in ~~stock,~~sales atof ~~that~~the ~~time,~~licensed ~~increased~~products ~~from~~during ~~4,250,000~~each tocalendar ~~29,900,000~~year ~~shares,~~of ~~all with~~the aterm, ~~par~~excluding ~~value~~the offirst $0year.~~001.~~

~~The~~ Closing ~~forward~~of ~~stock~~the ~~split~~transaction ~~was~~is ~~approved~~subject byto ~~the~~completion ~~Financial~~of ~~Industry Regulatory~~due ~~Authority~~diligence ~~(FINRA)~~and ~~with~~to anthe ~~effective~~transfer ~~date~~ of ~~August~~the 19Biomatrix, ~~2014~~Arizona securities to our Company. Biomatrix Arizona will become our wholly owned subsidiary upon completion of the transaction.

OnOur ~~November~~Current 25, 2014, our board of directors approved an agreement and plan of merger to merge with our wholly-owned subsidiary Science to Consumers, Inc., a Nevada corporation, to effect a name change from Argan Beauty Corp. to Science to Consumers, Inc. Science to Consumers, Inc. was formed solely for the change of name.Products

~~Articles~~We ofare ~~Merger~~currently toselling ~~effect~~six products ~~the~~that ~~merger~~are ~~and~~available ~~change~~to ofbe ~~name~~purchased ~~were filed~~through ~~and~~our ~~became~~website, ~~effective~~and ~~with~~wholesale orders ~~the~~are ~~Nevada~~also ~~Secretary~~being ofaccepted ~~State~~from onJune ~~December 23~~1, ~~2014.~~ 2016. The ~~name~~Company ~~change~~plans ~~was~~on ~~reviewed~~engaging byin ~~the~~an e-commerce ~~FINRA~~strategy ~~and~~to ~~was~~be ~~approved~~able ~~for~~to ~~filing~~drive ~~with an~~its ~~effective~~online ~~date~~sales. In ~~of December 24~~addition, ~~2014.~~the ~~The~~company ~~name~~is ~~change~~targeting cosmetic ~~became~~distribution ~~effective~~companies ~~with the~~in ~~Over-the-Counter~~China ~~Bulletin~~and ~~Board~~Hong atKong ~~the~~as ~~opening~~part of ~~trading~~its ~~on December 24, 2014 under the symbol "BEUT"~~sales strategy. ~~Our CUSIP number is 808645105.~~

~~Effective~~The ~~August~~Company ~~18,~~is ~~2015,~~also ~~Burt~~working ~~Ensley~~with ~~resigned~~the Licensee asto ~~chief executive~~re-design ~~officer~~and ofre-package ~~our~~the ~~company.~~product ~~Mr.~~line ~~Ensley~~to ~~will~~better ~~remain~~reflect ~~as a company advisor. In connection with~~ the Chinese ~~resignation~~market ~~of Mr~~place. ~~Ensley, Edwon Lam was appointed as chief executive officer.~~

~~Mr.~~The ~~Ensley's~~products ~~resignation~~being ~~was~~sold ~~not~~by the ~~result~~Company currently ofare ~~any~~Dermalastyl ~~disagreement with~~Facial ~~our~~Scrub, ~~company~~Dermalastyl ~~regarding~~Bx ~~our~~Pro, ~~operations~~Dermalastyl Bx Elastropin, Dermalastyl-e ~~policies~~Intensive Eye Serum, ~~practices~~Dermalastyl-m orWrinkle ~~otherwise~~Eye Radicator, Dermalastyl-m Anti- Wrinkle after shave for Men.

~~Our~~ Results ~~principal~~of ~~executive~~Operations ~~office~~for isthe ~~located~~Three atand ~~Faraday~~Nine ~~Str.~~Months ~~31, Leipzig,~~Ended ~~Germany~~February 29, ~~04159.~~2016 ~~Our~~and ~~telephone~~February ~~number~~28, ~~is 49 (0) 173 8264 717.~~ 2015

~~Our~~ The ~~Current~~following ~~Business~~summary of our results of operations should be read in conjunction with our unaudited financial statements for the Nine months ended February 29, 2016 and February 28, 2015.

On Our ~~October~~operating 1,results ~~2013,~~for ~~Science~~the tothree ~~Consumers~~and ~~Inc.,~~Nine amonths ~~private~~ended ~~Nevada corporation~~February ~~(the “Assignor”)~~29, ~~entered~~2016 ~~into~~and aFebruary ~~License Agreement with Protein Genomics Inc.~~28, a2015are ~~Delaware~~summarized ~~corporation,~~as ~~pursuant to which the Assignor acquired the rights from Protein Genomics Inc. to sell certain products.~~follows:

On January 19, 2015, our company, as assignee, entered into an Assignment Agreement with the Assignor, pursuant to which we have acquired the right, title and interest to the License Agreement and all obligations, benefits and advantages thereunder in relation to the territory under the License Agreement for consumer skin care products supplied by Protein Genomics. Under the terms of the Assignment Agreement, Burt Ensley, the current sole director and officer of the Assignor and a former chief executive officer of our company, shall be issued 2,000,000 shares of common stock of our company as consideration for the transfer of the License Agreement.

		Three Months Ended						Nine Months Ended
		February 29			February 28			February 29			February 28
		2016			2015			2016			2015
Advertising and promotion	$	Nil		$	Nil		$	Nil		$	15
Amortization expense	$	291		$	Nil		$	581		$	Nil
Bank service charges	$	Nil		$	48		$	Nil		$	169
Professional fees	$	18,501		$	11,866		$	34,449		$	40,856
Net Loss	$	(18,792	)	$	(11,914	)	$	(35,030	)	$	(41,040	)

7Our net loss for the three months ended February 29, 2016 was $18,792 compared to a net loss of $11,914 for the same period in 2015. Our net loss for Nine months ended February 28, 2016 was $35,030 compared to a net loss of $41,040 during the same period in 2015. During the Nine months ended February 29, 2016 we did not generate any revenue.

~~Under~~During the ~~License~~three ~~Agreement~~months ~~our~~ended ~~company~~February ~~will~~29, ~~provide~~2016, ~~direct~~our tooperating ~~consumer~~expenses ~~sales,~~were ~~marketing~~amortization ~~and~~expenses ~~distribution~~ of ~~finished~~$291 ~~consumer~~and ~~skin~~professional ~~care products~~fees ~~provided~~of by$18,501. During ~~Protein~~the ~~Genomics~~three ~~via~~months ~~direct~~ended ~~response~~February ~~advertisements~~28, ~~and other~~2015, ~~worldwide~~our ~~marketing~~operating ~~and~~expenses ~~distribution~~were bank ~~channels.~~service ~~Our~~charges ~~company~~of ~~will~~$48 ~~create direct~~and ~~response~~professional ~~advertisements~~fees ~~for~~of ~~the~~$11,866. ~~products~~The increase in operating ~~consultation~~expenses ~~with~~for ~~Protein Genomics,~~this ~~which~~period ~~shall~~compared ~~initially~~to ~~consist~~the ofprevious ~~direct~~period ~~response~~is ~~print advertisements~~primarily ~~and~~due ~~television~~to ~~commercials~~an ~~and~~increase ~~other~~in ~~forms~~professional ~~of direct response advertisements~~fees.

~~Our~~During ~~company~~the ~~shall~~Nine ~~manage~~months ~~all~~ended ~~creative~~February ~~testing~~29, ~~media~~2016, ~~buying,~~our operating ~~telemarketing~~expenses ~~fulfillment~~were ~~and~~amortization ~~credit~~expenses ~~card~~of ~~processing~~$581 ~~relating~~and toprofessional ~~the~~fees ~~sale~~ of ~~the~~$34,449. ~~consumer~~During ~~skin~~the ~~care~~Nine ~~products~~months ~~through~~ended ~~direct~~February ~~response~~28, ~~advertisements~~2015, ~~and~~our ~~will~~operating ~~work~~expenses were ~~with~~advertising ~~Protein~~and ~~Genomics~~promotion onof ~~appropriate~~$15, ~~publicity~~bank ~~and~~service ~~home~~charges ~~shopping~~of ~~opportunities~~$169 and professional ~~for~~fees ~~the~~of ~~products~~$40,856. WeThe ~~may~~decrease ~~also~~in ~~work~~operating ~~together~~expenses ~~with~~for ~~respect~~this toperiod compared to the ~~packaging~~previous ofperiod ~~the products~~is primarily due a decrease in professional fees.

~~Our~~The ~~company~~weighted ~~may~~average ~~also~~number ~~present~~of ~~buying~~shares ~~opportunities~~outstanding ~~online~~were 30,465,000 ofand ~~the products~~29,900,000 asfor ~~part~~the ofNine ~~our~~months ~~overall~~ended ~~web~~February ~~strategy~~29, ~~including~~2016 ~~order~~and February ~~acceptance~~28, ~~billing and~~2015, ~~collection~~respectively.

~~Protein~~Liquidity ~~Genomics will provide our company with finished inventory, claims substantiation with respect to each product including any relevant clinical data~~ and ~~support~~Financial for any such claims, assistance in securing testimonials and cooperation from experts and arranging for appearances by our former chief executive officer, Burt Ensley, to promote the products in our direct response advertising channels. Protein Genomics will also provide us with fully cleared content required by our company to create the direct response advertisements, ensure that any patents and intellectual property are in good standing and defend against any potential competition or infringement. Condition

The terms of the Assignment Agreement signed on January 19, 2015 have not been met and a new agreement with similar terms and pricing were negotiated and entered into on December 29, 2015.

Working Capital
		At February 29			At May 31,
		2016			2015
Current Assets	$	Nil		$	1,749
Current Liabilities	$	38,893		$	8,891
Working Capital Deficit	$	(38,893	)	$	(7,142	)

Effective December 29, 2015, we entered into an exclusive license agreement with Biomatrix Inc., a Delaware corporation, pursuant to which we obtained the exclusive rights to sell certain proprietary skincare products of Biomatrix by direct to consumer marketing and sales in the territories of China and Europe. In consideration for the marketing, sales and distribution services to be provided by our company, Biomatrix has agreed to supply product inventory at a rate not less favorable than that provided to any third party. Additionally, Biomatrix has agreed to transfer to our company 100% equity ownership of Biomatrix Inc., an Arizona corporation which holds all right and title to the product distribution rights acquired. In consideration of transfer of title and rights acquired, we agreed to issue to Biomatrix (Delaware) 2,000,000 restricted common shares in the capital stock of our company.

Cash Flows
		At February 29			At February 28,
		2016			2015
Net cash used in operations	$	(20,597	)	$	(41,040	)
Net cash (used in) provided by investing activities	$	Nil		$	Nil
Net cash (used in) provided by financing activities	$	18,848		$	45,674
Increase (Decrease) in Cash During the Period	$	(1,749	)	$	4,634

~~The~~As ~~initial~~at ~~term~~February of29, ~~the~~2016, ~~exclusive~~our ~~license~~total ~~agreement~~assets iswere ~~for~~$9,871 5compared ~~years~~to $1,749 ~~subject~~in tototal ~~our~~assets ~~company~~at ~~achieving~~May ~~minimum~~31, ~~sales~~2015. ofTotal ~~$250,000~~assets ~~and~~were comprised of $~~500~~9,~~000~~871 ~~during~~in ~~the~~website ~~first~~development ~~and~~costs, ~~second~~as ~~years~~at ofFebruary ~~the agreement~~29, ~~respectively.~~2016 ~~Thereafter, the~~we ~~term~~had ~~will~~no ~~automatically~~cash ~~renew~~or ~~for~~cash equivalents. ~~successive~~As 5at ~~year~~February ~~periods~~29, ~~provided~~2016, ~~that~~our ~~we achieve~~current aliabilities ~~minimum~~were $~~500~~38,~~000~~893 compared to $8,891 in ~~sales~~current ofliabilities ~~the~~as ~~licensed~~at ~~products~~May ~~during~~31, ~~each~~2015. Stockholders’ ~~calendar~~deficit ~~year~~was $29,022 as of ~~the~~February29, ~~term~~2016 compared to stockholders' deficit of $7,142 ~~excluding~~as ~~the~~of ~~first~~May ~~year~~31, 2015.

~~Closing~~Cash ofFlows ~~the~~from ~~transaction~~Operating is subject to completion of due diligence and to the transfer of the Biomatrix, Arizona securities to our Company. Biomatrix Arizona will become our wholly owned subsidiary upon completion of the transaction. Activities

~~Results~~We ofhave ~~Operations~~not ~~for~~generated positive cash flows from operating activities. For the ~~Three~~Nine ~~and~~months ~~Six~~ended ~~Months~~February ~~Ended~~29, 2016, net cash flows used in ~~November~~operating 30activities was $20,597 ~~2015~~compared ~~and~~to ~~2014~~$41,040 for the Nine months ended February 28, 2015.

~~The~~Cash ~~following~~Flows ~~summary~~from ofInvesting ~~our results of operations should be read in conjunction with our unaudited financial statements for the six months ended November 30, 2015 and 2014.~~Activities

~~Our~~For ~~operating~~the ~~results~~Nine ~~for~~months ~~the~~ended ~~three~~February ~~and~~29, ~~six~~2016 ~~months~~cash ~~ended~~flows used in ~~November~~investing ~~30,~~activities ~~2015~~were ~~and~~$0 ~~2014~~compared ~~are~~to ~~summarized~~$0 asfor ~~follows:~~the Nine months ended February 28, 2015.

		Three Months Ended				Six Months Ended
		November 30,				November 30,
		2015		2014		2015		2014
Advertising and promotion	$	Nil	$	Nil	$	Nil	$	15

Cash Flows from Financing Activities

8For the Nine months ended February 29, 2016 cash flows from financing activities were $18,848 compared to $45,674 for the Nine months ended February 28, 2015.

		Three Months Ended						Six Months Ended
		November 30,						November 30,
		2015			2014			2015			2014
Amortization expense	$	290		$	Nil		$	290		$	Nil
Bank service charges	$	Nil		$	60		$	Nil		$	120
Professional fees	$	11,831		$	25,327		$	15,948		$	28,990
Net Loss	$	(12,121	)	$	(25,387	)	$	(16,238	)	$	(29,125	)

Plan of Operation and Future Financings

~~Our~~We ~~net~~expect ~~loss~~that ~~for~~working ~~the~~capital ~~three~~requirements ~~months~~will ~~ended~~continue ~~November~~to ~~30, 2015 was~~be ~~$12,121.~~funded ~~Our~~through ~~net~~a ~~loss~~combination ~~for~~of ~~six~~our ~~months~~existing ~~ended~~funds ~~November~~and ~~30,~~further ~~2015~~issuances ~~was $16,238~~of securities. ~~During the~~Our ~~six~~working ~~months~~capital ~~ended~~requirements ~~November~~are ~~30,~~expected ~~2015~~to weincrease ~~did~~in ~~not~~line with ~~generate~~the ~~any~~growth ~~revenue~~of our business.

~~During~~Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next three months. ~~ended~~We ~~November~~have ~~30,~~no ~~2015~~lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) acquisition of inventory; (ii) developmental expenses ~~were~~associated ~~amortization~~with a start-up business; and (iii) marketing expenses. We intend to finance these expenses with further issuances of ~~$290~~securities, and ~~professional~~debt ~~fees~~issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of ~~$11~~equity or convertible debt securities will result in dilution to our current shareholders. Further,~~831~~ such securities might have rights, preferences or privileges senior to our common stock. Additional ~~During~~financing ~~the~~may ~~three~~not ~~months~~be ~~ended~~available ~~November~~upon 30acceptable terms, ~~2014~~or at all. If adequate funds are not available or are not available on acceptable terms, ~~our~~we ~~operating~~may ~~expenses~~not ~~were~~be ~~bank~~able ~~service~~to ~~charges~~take advantage of ~~$60~~prospective ~~and~~new ~~professional~~business ~~fees~~endeavors ofor ~~$25~~opportunities,~~327~~ which could significantly and materially restrict our business operations. ~~The~~We will ~~decrease~~have to raise additional funds in ~~operating~~ ~~expenses~~the ~~for~~next ~~this~~twelve ~~period~~months ~~compared~~in order to sustain and expand our operations. We currently do not have a specific plan of how we will obtain such funding; however, we anticipate that additional funding will be in the ~~previous~~form ~~period~~of isequity ~~primarily~~financing from the sale of our common stock. We ~~due~~have and will continue to aseek ~~decrease~~to obtain short-term loans from our directors, although no future arrangement for additional loans has been made. We do not have any agreements with our directors concerning these loans. We do not have any arrangements in ~~professional~~place ~~fees~~for any future equity financing.

~~During~~Cash ~~the~~Requirements six months ended November 30, 2015, our operating expenses were amortization expenses of $290 and professional fees of $15,948. During the six months ended November 30, 2014, our operating expenses were advertising and promotion of $15, bank service charges of $120 and professional fees of $28,990. The decrease in operating expenses for this period compared to the previous period is primarily due to a decrease in professional fees.

~~The~~We ~~weighted~~estimate ~~average~~our ~~number~~operating ofexpenses ~~shares~~and ~~outstanding~~working ~~were~~capital ~~29,908,852~~requirements ~~and 29,900,000~~ for the ~~six~~twelve ~~months~~month ~~ended~~period ~~November~~to ~~30,~~be ~~2015~~as ~~and November 30, 2014, respectively.~~ follows:

Liquidity and Financial Condition

Estimated Expenses For the Twelve Month Period ending February 28, 2017

Professional fees	$	30,000
Establishing an office in China	$	13,000
Online Advertising	$	5,000
Import Licenses		3,500
General and administrative expenses		60,000
Total	$	111,500

~~Working~~ At ~~Capital~~present, our cash requirements for the next 12 months outweigh the funds available to maintain our operations or development of any future properties. Of the $111,500 that we require for the next 12 months, we had $0 in cash as of February 29, 2016, and a working capital deficit of $38,893. Until we complete a transaction, acquisition or business combination, our cash requirements will be in regards to maintaining our corporate existence, and ensuring compliance with our SEC continuous disclosure obligations, including our financial reporting requirements. In addition, we will require additional capital in order to investigate and conclude any future transaction, acquisition or business combination. In order to improve our liquidity, we plan to pursue additional equity financing from private investors or possibly a registered public offering. We do not currently have any definitive arrangements in place for the completion of any further private placement financings and there is no assurance that we will be successful in completing any further private placement financings. If we are unable to achieve the necessary additional financing, then we plan to reduce the amounts that we spend on our business activities and administrative expenses in order to be within the amount of capital resources that are available to us.

		At November 30,			At May 31,
		2015			2015
Current Assets	$	614		$	1,749
Current Liabilities	$	28,156		$	8,891
Working Capital	$	(27,542	)	$	(7,142	)

Contractual Obligations

~~Cash~~ As ~~Flows~~a “smaller reporting company”, we are not required to provide tabular disclosure obligations.

		At November 30			At November 30,
		2015			2014
Net cash used in operations	$	3,317		$	(29,125	)
Net cash (used in) provided by investing activities	$	(10,452	)	$	Nil
Net cash (used in) provided by financing activities	$	6,000		$	46,998
Increase (Decrease) in Cash During the Period	$	(1,135	)	$	17,873

Going Concern

As We athave ~~November~~suffered ~~30,~~recurring ~~2015,~~losses from operations and are dependent on our ~~total~~ability ~~assets~~to ~~were~~raise ~~$614~~capital ~~compared~~from stockholders or other sources to ~~$1,749~~ inmeet ~~total~~our ~~assets~~obligations atand ~~May~~repay ~~31,~~our ~~2015.~~liabilities ~~Total~~arising ~~assets~~from ~~were~~normal ~~comprised~~business ofoperations ~~$614~~when inthey become due. In ~~cash~~their ~~and~~report ~~cash~~on ~~equivalents.~~our Asaudited atfinancial ~~November~~statements 30for the year ended May 31, 2015, our ~~current~~independent ~~liabilities~~auditors ~~were $28,156~~included ~~compared~~an toexplanatory ~~$8,891~~paragraph inregarding ~~current~~concerns ~~liabilities~~about asour atability ~~May~~to ~~31,~~continue ~~2015~~as a going concern. ~~Stockholders’~~ ~~equity~~Our ~~was~~financial ~~($17,380)~~statements ascontain additional ofnote ~~November~~disclosure ~~30,~~describing ~~2015~~the ~~compared~~circumstances ~~to stockholders'~~that ~~equity~~lead ofto ~~($7,142)~~this asdisclosure ofby ~~May~~our ~~31,~~independent ~~2015~~auditors.

~~Cash~~ Off-Balance ~~Flows~~Sheet ~~from Operating Activities~~Arrangements

We have ~~not~~no ~~generated~~off-balance ~~positive~~sheet ~~cash~~arrangements ~~flows~~that ~~from~~have ~~operating activities.~~or ~~For~~are ~~the~~reasonably ~~six~~likely ~~months~~to ~~ended~~have ~~November~~a ~~30,~~current ~~2015,~~or ~~net~~future ~~cash~~effect ~~flows~~on ~~used~~our ~~in operating~~financial ~~activities~~condition, ~~was~~changes $7in financial condition,~~135~~ ~~compared~~revenues toor ~~$29~~expenses,~~125~~ ~~for~~results ~~the~~of ~~six~~operations, ~~months~~liquidity, ~~ended~~capital expenditures ~~November~~or ~~30,~~capital ~~2014.~~resources that is material to stockholders.

9 Critical Accounting Policies

~~Cash~~ Basis ~~Flows~~of ~~from Investing Activities~~Presentation

~~For~~ The ~~the~~financial ~~six~~statements ~~months~~of ~~ended~~our ~~November~~company ~~30,~~have ~~2015~~been ~~cash~~prepared ~~flows used~~ in ~~investing~~ ~~activities~~accordance ~~were~~with ~~$10,452~~generally ~~compared~~accepted toaccounting ~~$0for~~principles in the ~~six~~United ~~months~~States ~~ended November~~of ~~30,~~America ~~2014~~and are presented in US dollars.

~~Cash~~ Accounting ~~Flows from Financing Activities~~Basis

~~For~~ Our company uses the ~~six~~accrual ~~months~~basis ~~ended~~of ~~November~~accounting ~~30,~~and ~~2015~~accounting ~~cash~~principles ~~flows~~generally ~~from financing~~accepted ~~activities~~in ~~were~~the ~~$6,000~~United ~~compared~~States toof ~~$46,998~~America ~~for~~(“GAAP” ~~the~~accounting). ~~six~~Our ~~months~~company ~~ended November~~has ~~30,~~adopted ~~2014.~~a May 31 fiscal year end.

~~Plan~~ Cash ~~of Operation~~ and ~~Future~~Cash ~~Financings~~ Equivalents

We Our ~~expect~~company ~~that~~considers ~~working~~all ~~capital~~highly ~~requirements~~liquid ~~will~~investments ~~continue~~with tothe ~~be funded~~original ~~through~~maturities ~~a combination~~ of ~~our~~three ~~existing~~months ~~funds~~or ~~and~~less ~~further~~to ~~issuances~~be ~~of securities~~cash equivalents. Our ~~working~~company ~~capital~~had ~~requirements~~$nil ~~are~~of ~~expected~~cash toas ~~increase~~of inFebruary ~~line with~~29, ~~the~~2016 ~~growth~~and $1,749 of ~~our~~cash ~~business.~~as of May 31, 2015.

~~Existing working capital, further advances and debt~~ ~~instruments,~~Fair ~~and~~Value ~~anticipated cash flow are expected to be adequate to fund our operations over the next three months. We have no lines~~ of ~~credit~~Financial or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) acquisition of inventory; (ii) developmental expenses associated with a start-up business; and (iii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations. We will have to raise additional funds in the next twelve months in order to sustain and expand our operations. We currently do not have a specific plan of how we will obtain such funding; however, we anticipate that additional funding will be in the form of equity financing from the sale of our common stock. We have and will continue to seek to obtain short-term loans from our directors, although no future arrangement for additional loans has been made. We do not have any agreements with our directors concerning these loans. We do not have any arrangements in place for any future equity financing. Instruments

~~Cash~~ Our ~~Requirements~~company’s financial instruments consist of cash and cash equivalents and amounts due to shareholder. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

~~We estimate our operating expenses and working capital~~ ~~requirements~~Website ~~for~~Development ~~the twelve month period to be as follows:~~ Costs

Estimated Expenses For the Twelve Month Period ending November 30, 2016
Professional fees	$	30,000
Establishing an office	$	13,000
Advertising	$	5,000
Website development		3,500
General and administrative expenses		60,000
Total	$	111,500

Website development costs consist of costs incurred to develop internet websites to promote, advertise, and earn revenue with respect to our company’s business operations. Costs are amortized on a straight line basis over 3 years from when the internet web site has been completed.

~~At present, our cash requirements for the next 12 months~~ ~~outweigh~~Income ~~the~~Taxes funds available to maintain our operations or development of any future properties. Of the $111,500 that we require for the next 12 months, we had $614 in cash as of November 30, 2015, and a working capital deficit of $27,542. Until we complete a transaction, acquisition or business combination, our cash requirements will be in regards to maintaining our corporate existence, and ensuring compliance with our SEC continuous disclosure obligations, including our financial reporting requirements. In addition, we will require additional capital in order to investigate and conclude any future transaction, acquisition or business combination. In order to improve our liquidity, we plan to pursue additional equity financing from private investors or possibly a registered public offering. We do not currently have any definitive arrangements in place for the completion of any further private placement financings and there is no assurance that we will be successful in completing any further private placement financings. If we are unable to achieve the necessary additional financing, then we plan to reduce the amounts that we spend on our business activities and administrative expenses in order to be within the amount of capital resources that are available to us.

10 Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

~~Contractual~~ Use ~~Obligations~~of Estimates

As The apreparation ~~“smaller~~of ~~reporting~~financial ~~company”,~~statements wein ~~are~~conformity ~~not~~with ~~required~~generally accepted accounting principles requires management to ~~provide~~ ~~tabular~~make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure ~~obligations~~of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

~~Going~~ Revenue ~~Concern~~Recognition

We Our ~~have~~company ~~suffered~~recognizes ~~recurring~~revenue ~~losses~~when ~~from~~products ~~operations and~~ are ~~dependent~~ onfully ~~our~~delivered ~~ability to raise capital from stockholders~~ or ~~other~~services ~~sources~~have ~~to meet~~been ~~our~~provided ~~obligations~~ and ~~repay~~collection ~~our~~is ~~liabilities~~reasonably ~~arising from normal business operations when they become due~~assured. In their report on our audited financial statements for the year ended May 31, 2015, our independent auditors included an explanatory paragraph regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosure describing the circumstances that lead to this disclosure by our independent auditors.

~~Off~~ Stock-~~Balance~~Based ~~Sheet~~Compensation ~~Arrangements~~

~~We have no off~~ Stock-~~balance~~based ~~sheet~~compensation ~~arrangements~~is ~~that~~accounted ~~have~~for orat ~~are reasonably~~fair ~~likely~~value toin ~~have~~accordance awith ~~current~~ASC orTopic ~~future~~718. ~~effect~~To ondate, our ~~financial~~company ~~condition, changes~~has innot ~~financial~~adopted ~~condition,~~a ~~revenues~~stock oroption ~~expenses,~~plan ~~results~~and ofhas ~~operations, liquidity,~~not ~~capital~~granted ~~expenditures~~any orstock ~~capital resources that is material to stockholders~~options.

~~Critical~~ Basic ~~Accounting~~Income ~~Policies~~(Loss) Per Share

~~Basis~~ Basic income (loss) per share is calculated by dividing our company’s net loss applicable to common shareholders by the weighted average number of ~~Presentation~~common shares during the period. Diluted earnings per share is calculated by dividing our company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of February 29, 2016 and May 31, 2015.

~~The financial statements of our company have been prepared in~~ ~~accordance~~Comprehensive ~~with~~Income ~~generally accepted accounting principles in the United States of America and are presented in US dollars.~~

~~Accounting~~ Our ~~Basis~~company has which established standards for reporting and display of comprehensive income, its components and accumulated balances. When applicable, our company would disclose this information on its Statement of Stockholders’ Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. Our company has not had any significant transactions that are required to be reported in other comprehensive income.

~~Our~~Recent ~~company~~Accounting ~~uses~~Pronouncements ~~the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting). Our company has adopted a May 31 fiscal year end.~~

~~Cash~~Our ~~and~~company ~~Cash~~does ~~Equivalents~~not expect the adoption of any other recent accounting pronouncements to have a material impact on our financial statements.

~~Our~~Item ~~company considers all highly liquid investments with the original maturities of three months or less to be cash equivalents~~3. ~~Our~~Quantitative ~~company had $614 of cash as of November 30, 2015~~ and ~~$1,749~~Qualitative ofDisclosures ~~cash~~About asMarket ~~of May 31, 2015.~~Risk

~~Fair~~As ~~Value~~a of“smaller ~~Financial~~reporting ~~Instruments~~company”, we are not required to provide the information required by this Item.

~~Our~~Item ~~company’s~~4. ~~financial~~Controls ~~instruments consist of cash~~ and cash equivalents and amounts due to shareholder. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.Procedures

11Management’s Report on Disclosure Controls and Procedures

~~Website~~We ~~Development~~maintain ~~Costs~~disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer (our principal executive officer) and chief financial officer (our principal financial officer and principal accounting officer), to allow for timely decisions regarding required disclosure.

~~Website~~As ~~development~~of ~~costs~~the ~~consist~~end of ~~costs~~our ~~incurred~~quarter tocovered ~~develop internet~~by ~~websites~~this ~~to promote~~report, ~~advertise~~we carried out an evaluation, ~~and~~under ~~earn~~the ~~revenue~~supervision and with ~~respect~~the toparticipation of our chief ~~company’s~~executive ~~business~~officer ~~operations.~~(our ~~Costs~~principal ~~are~~executive ~~amortized~~officer) and our chief financial officer (our principal financial officer and principal accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures. Based on athe ~~straight~~foregoing, ~~line~~our ~~basis~~chief ~~over~~executive officer (our principal 3executive ~~years~~officer) ~~from~~and ~~when~~our chief financial officer (our principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective in providing reasonable assurance in the reliability ~~internet~~of ~~web~~our ~~site~~reports ~~has~~as ~~been~~of ~~completed~~the end of the period covered by this quarterly report.

~~Income~~Changes ~~Taxes~~in Internal Control over Financial Reporting

~~Income~~During ~~taxes are computed using~~ the ~~asset~~period ~~and~~covered ~~liability~~by ~~method. Under~~this ~~the~~report ~~asset~~there ~~and~~were ~~liability~~no ~~method, deferred income tax assets and liabilities~~changes ~~are~~in ~~determined~~our ~~based~~internal oncontrol ~~the~~over ~~differences between the~~ financial reporting ~~and~~that ~~tax bases~~materially ofaffected, ~~assets and liabilities and~~ or are ~~measured~~reasonably ~~using~~likely ~~the~~to ~~currently~~materially ~~enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that~~affect, ~~based~~our oninternal ~~available~~control ~~evidence,~~over ~~are not expected to be realized~~financial reporting.

~~Use~~PART ofII ~~Estimates~~– OTHER INFORMATION

~~The~~Item preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period1. ~~Actual~~Legal ~~results could differ from those estimates.~~ Proceedings

~~Revenue~~We ~~Recognition~~know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

~~Our~~Item ~~company~~1A. ~~recognizes~~Risk ~~revenue when products are fully delivered or services have been provided and collection is reasonably assured.~~ Factors

~~Stock-Based~~As ~~Compensation~~a “smaller reporting company”, we are not required to provide the information required by this Item.

~~Stock-based~~Item ~~compensation is accounted for at fair value in accordance with ASC Topic 718~~2. ToUnregistered ~~date,~~Sales ~~our~~of ~~company~~Equity ~~has~~Securities ~~not adopted a stock option plan~~ and ~~has~~Use ~~not~~of ~~granted any stock options.~~ Proceeds

~~Basic~~None. ~~Income (Loss) Per Share~~

~~Basic~~Item ~~income (loss) per share is calculated by dividing our company’s net loss applicable to common shareholders by the weighted average number of common shares during the period~~3. ~~Diluted~~Defaults ~~earnings~~Upon ~~per~~Senior share is calculated by dividing our company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of November 30, 2015 and May 31, 2015. Securities

~~Comprehensive~~None. ~~Income~~

~~Our~~Item ~~company has which established standards for reporting and display of comprehensive income, its components and accumulated balances~~4. ~~When applicable,~~Mine ~~our~~Safety company would disclose this information on its Statement of Stockholders’ Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. Our company has not had any significant transactions that are required to be reported in other comprehensive income. Disclosures

~~Recent~~Not ~~Accounting~~applicable. ~~Pronouncements~~

~~Our~~Item ~~company~~5. ~~does~~Other ~~not expect the adoption of any other recent accounting pronouncements to have a material impact on our financial statements.~~ Information

12On April 7, 2016, KLJ & Associates, LLP resigned as our independent registered public accounting firm.

~~Item~~The 3.reports ~~Quantitative~~of KLJ & Associates, LLP on our financial statements as of and ~~Qualitative~~for ~~Disclosures~~the ~~About~~fiscal ~~Market~~years ~~Risk~~ended May 31, 2015 and 2014 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principle except to indicate that there was substantial doubt about our ability to continue as a going concern.

AsDuring athe ~~“smaller~~fiscal ~~reporting~~years ~~company”~~ended May 31, we2015 ~~are~~and 2014, there have been no disagreements with KLJ & Associates, LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not ~~required~~resolved to the satisfaction KLJ & ~~provide~~Associates, LLP would have caused them to make reference thereto in connection with their report on the ~~information~~financial ~~required~~statements byfor ~~this~~such ~~Item~~years.

~~Item~~On 4.April ~~Controls~~25, ~~and~~2016, ~~Procedures~~our company engaged Yichien Yeh, CPA as its new independent registered public accounting firm.

~~Management’s~~Item ~~Report~~6. ~~on Disclosure Controls and Procedures~~ Exhibits

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer (our principal executive officer) and chief financial officer (our principal financial officer and principal accounting officer), to allow for timely decisions regarding required disclosure.

Exhibit Number	Description

(3)	Articles of Incorporation and Bylaws
3.1	Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on August 6, 2013)
3.2	Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on August 6, 2013)
3.3	Certificate of Change (incorporated by reference to our Current Report on Form 8-K filed on August 22, 2014)
3.4	Articles of Merger (incorporated by reference to our Current Report on Form 8-K filed on December 30, 2014)

(10)	Material Contracts
10.1	Web Site Design Agreement between our company and Smart Creations (incorporated by reference to our Registration Statement on Form S-1 filed on August 6, 2013)
10.2	License Assignment Agreement dated January 19, 2015 (incorporated by reference to our Current Report on Form 8-K filed on February 5, 2015)
10.3	Exclusive License Agreement dated December 16, 2015 between the Company and Biomatrix Inc. (incorporated by reference to our Current Report on Form 8-K filed on January 6, 2016)

(31)	Rule 13a-14(a) / 15d-14(a) Certifications
31.1*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
31.2*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer

(32)	Section 1350 Certifications
32.1*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
32.2*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer

101	Interactive Data File
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

As* ofFiled the end of our quarter covered by this report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer (our principal executive officer) and our chief financial officer (our principal financial officer and principal accounting officer), of the effectiveness of the design and operation of our disclosure controls and proceduresherewith. Based on the foregoing, our chief executive officer (our principal executive officer) and our chief financial officer (our principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective in providing reasonable assurance in the reliability of our reports as of the end of the period covered by this quarterly report.

~~Changes~~SIGNATURES ~~in Internal Control over Financial Reporting~~

~~During~~Pursuant to the ~~period~~requirements ~~covered~~of bySection ~~this~~13 ~~report~~or ~~there~~15(d) ~~were~~of ~~no changes~~the inSecurities ~~our~~Exchange ~~internal~~Act ~~control~~of ~~over~~1934, ~~financial~~the ~~reporting~~registrant ~~that~~has ~~materially~~duly ~~affected,~~caused orthis report to ~~are~~be ~~reasonably~~signed ~~likely~~on toits ~~materially~~behalf ~~affect,~~by ~~our~~the ~~internal~~undersigned, ~~control~~thereunto ~~over~~duly ~~financial reporting~~authorized.

PART II – OTHER INFORMATION

	SCIENCE TO CONSUMERS, INC.
	*(Registrant)*



Dated: May 19, 2016	/s/ Vitaliy Gorelik
	Vitaliy Gorelik
	President, Chief Financial Officer, Treasurer and Director
	(Principal Financial Officer and Principal Accounting
	Officer)



Dated: May 19, 2016	/s/ Edwon Lam
	Edwon Lam
	Chief Executive Officer
	(Principal Executive Officer)

Item 1. Legal Proceedings

We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Pursuant to the exclusive license agreement entered into on December 29, 2015 with Biomatrix, we issued an aggregate of 2,000,000 common shares to one (1) person relying on the exemption from registration for “accredited investors” contained in Rule 506 of Regulation D of the Securities Act of 1933.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number	Description
(3)	Articles of Incorporation and Bylaws
3.1	Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on August 6, 2013)
3.2	Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on August 6, 2013)
3.3	Certificate of Change (incorporated by reference to our Current Report on Form 8-K filed on August 22, 2014)
3.4	Articles of Merger (incorporated by reference to our Current Report on Form 8-K filed on December 30, 2014)
(10)	Material Contracts
10.1	Web Site Design Agreement between our company and Smart Creations (incorporated by reference to our Registration Statement on Form S-1 filed on August 6, 2013)
10.2	License Assignment Agreement dated January 19, 2015 (incorporated by reference to our Current Report on Form 8-K filed on February 5, 2015)
10.3	Exclusive License Agreement dated December 16, 2015 between the Company and Biomatrix Inc. (incorporated by reference to our Current Report on Form 8-K filed on January 6, 2016)
(31)	Rule 13a-14(a) / 15d-14(a) Certifications
31.1*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
31.2*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(32)	Section 1350 Certifications
32.1*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
32.2*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
101	Interactive Data File
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SCIENCE TO CONSUMERS, INC.
	(Registrant)
Dated: January 22, 2016	/s/ Vitaliy Gorelik
	Vitaliy Gorelik
	President, Chief Financial Officer, Treasurer and Director
	(Principal Financial Officer and Principal Accounting
	Officer)
Dated: January 22, 2016	/s/ Edwon Lam
	Edwon Lam
	Chief Executive Officer
	(Principal Executive Officer)

Filing Compare · Science to Consumers, Inc.